Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation

Author(s): Yan-Si Xiong, Dan-Li Wang, Lu Tan, Xiong Wang, Li-Ming Chen, Cheng-Xin Gong, Jian-Zhi Wang, Ling-Qiang Zhu

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 12 , Issue 3 , 2013

Become EABM
Become Reviewer


One of the neuropathological hallmarks of Alzheimer’s disease (AD) is the occurrence of neurofibrillary tangles (NFTs) that are composed of abnormally hyperphosphorylated microtubule-associated protein tau. Abnormal tau hyperphosphorylation is mainly induced due to the imbalance between protein kinases and phosphatases. In the tanglerich subregions of the hippocampus and parietal cortex in the brain of AD patients, the levels of the phosphorylationdependent protein peptidyl-prolyl cis-trans isomerase (Pin1) were found to be low. Although Pin1 can regulate tau phosphorylation, it is not clear whether the inhibition of glycogen synthase kinase 3 (GSK-3), the primary mediator of tau phosphorylation in AD, could reverse tau hyperphosphorylation induced due to the down-regulation of Pin1. We found that while suppression of Pin1, either by using its inhibitor Juglone or a shRNA plasmid against Pin1, induces tau hyperphosphorylation and GSK-3β activation both in vivo and in vitro, inhibition of GSK-3β by SB216763 or LiCl reverses tau hyperphosphorylation. Our data suggest that GSK-3β activation plays an important role in tau hyperphosphorylation induced by the down-regulation of Pin1, and the inhibition of GSK-3β might be a potential therapeutic approach for AD pathology.

Keywords: Alzheimer’s disease, GSK-3β, phosphorylation, Pin1, SB216763, shRNA, tau.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [436 - 443]
Pages: 8
DOI: 10.2174/1871527311312030016
Price: $65

Article Metrics

PDF: 21